These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 37492687)

  • 21. High-Grade Glioma Treatment Response Monitoring Biomarkers: A Position Statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 1: Perfusion and Diffusion Techniques.
    Henriksen OM; Del Mar Álvarez-Torres M; Figueiredo P; Hangel G; Keil VC; Nechifor RE; Riemer F; Schmainda KM; Warnert EAH; Wiegers EC; Booth TC
    Front Oncol; 2022; 12():810263. PubMed ID: 35359414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hemodynamic Imaging in Cerebral Diffuse Glioma-Part B: Molecular Correlates, Treatment Effect Monitoring, Prognosis, and Future Directions.
    Stumpo V; Guida L; Bellomo J; Van Niftrik CHB; Sebök M; Berhouma M; Bink A; Weller M; Kulcsar Z; Regli L; Fierstra J
    Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment-related change versus tumor recurrence in high-grade gliomas: a diagnostic conundrum--use of dynamic susceptibility contrast-enhanced (DSC) perfusion MRI.
    Fatterpekar GM; Galheigo D; Narayana A; Johnson G; Knopp E
    AJR Am J Roentgenol; 2012 Jan; 198(1):19-26. PubMed ID: 22194475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival.
    Hu LS; Eschbacher JM; Heiserman JE; Dueck AC; Shapiro WR; Liu S; Karis JP; Smith KA; Coons SW; Nakaji P; Spetzler RF; Feuerstein BG; Debbins J; Baxter LC
    Neuro Oncol; 2012 Jul; 14(7):919-30. PubMed ID: 22561797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Dynamic Susceptibility Contrast Perfusion MRI in Glioma Progression Evaluation.
    Quan G; Zhang K; Liu Y; Ren JL; Huang D; Wang W; Yuan T
    J Oncol; 2021; 2021():1696387. PubMed ID: 33628239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
    Thomas AA; Arevalo-Perez J; Kaley T; Lyo J; Peck KK; Shi W; Zhang Z; Young RJ
    J Neurooncol; 2015 Oct; 125(1):183-90. PubMed ID: 26275367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic accuracy of dynamic contrast-enhanced perfusion MRI in stratifying gliomas: A systematic review and meta-analysis.
    Okuchi S; Rojas-Garcia A; Ulyte A; Lopez I; Ušinskienė J; Lewis M; Hassanein SM; Sanverdi E; Golay X; Thust S; Panovska-Griffiths J; Bisdas S
    Cancer Med; 2019 Sep; 8(12):5564-5573. PubMed ID: 31389669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pseudoprogression in high-grade glioma.
    Knudsen-Baas KM; Moen G; Fluge Ø; Storstein A
    Acta Neurol Scand Suppl; 2013; (196):31-7. PubMed ID: 23190289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advanced MR imaging techniques in the evaluation of nonenhancing gliomas: perfusion-weighted imaging compared with proton magnetic resonance spectroscopy and tumor grade.
    Sahin N; Melhem ER; Wang S; Krejza J; Poptani H; Chawla S; Verma G
    Neuroradiol J; 2013 Oct; 26(5):531-41. PubMed ID: 24199813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Additive Value of Magnetic Resonance Simulation Before Chemoradiation in Evaluating Treatment Response and Pseudoprogression in High-Grade Gliomas.
    Yadav D; Upadhyay R; Kumar VA; Chen MM; Johnson JM; Langshaw H; Curl BJ; Farhat M; Talpur W; Beckham TH; Yeboa DN; Swanson TA; Ghia AJ; Li J; Chung C
    Pract Radiat Oncol; 2024 Apr; ():. PubMed ID: 38685448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of unsupervised classification methods for brain tumor segmentation using multi-parametric MRI.
    Sauwen N; Acou M; Van Cauter S; Sima DM; Veraart J; Maes F; Himmelreich U; Achten E; Van Huffel S
    Neuroimage Clin; 2016; 12():753-764. PubMed ID: 27812502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imaging and Liquid Biopsy for Distinguishing True Progression From Pseudoprogression in Gliomas, Current Advances and Challenges.
    Li K; Zhu Q; Yang J; Zheng Y; Du S; Song M; Peng Q; Yang R; Liu Y; Qi L
    Acad Radiol; 2024 Aug; 31(8):3366-3383. PubMed ID: 38614827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating changes in radiation treatment volumes from post-operative to same-day planning MRI in High-grade gliomas.
    Champ CE; Siglin J; Mishra MV; Shen X; Werner-Wasik M; Andrews DW; Mayekar SU; Liu H; Shi W
    Radiat Oncol; 2012 Dec; 7():220. PubMed ID: 23259933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response Assessment in Neuro-Oncology Criteria for Gliomas: Practical Approach Using Conventional and Advanced Techniques.
    Leao DJ; Craig PG; Godoy LF; Leite CC; Policeni B
    AJNR Am J Neuroradiol; 2020 Jan; 41(1):10-20. PubMed ID: 31857322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment Response and Prognosis Evaluation in High-Grade Glioma: An Imaging Review Based on MRI.
    Zhou Q; Xue C; Ke X; Zhou J
    J Magn Reson Imaging; 2022 Aug; 56(2):325-340. PubMed ID: 35129845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of Advanced MR Imaging in Diagnosis of Neurological Malignancies: Current Status and Future Perspective.
    Eraky AM; Beck RT; Treffy RW; Aaronson DM; Hedayat H
    J Integr Neurosci; 2023 May; 22(3):73. PubMed ID: 37258452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic performance of advanced MRI in differentiating high-grade from low-grade gliomas in a setting of routine service.
    Chawalparit O; Sangruchi T; Witthiwej T; Sathornsumetee S; Tritrakarn S; Piyapittayanan S; Chaicharoen P; Direksunthorn T; Charnchaowanish P
    J Med Assoc Thai; 2013 Oct; 96(10):1365-73. PubMed ID: 24350420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imaging modalities in high-grade gliomas: pseudoprogression, recurrence, or necrosis?
    Caroline I; Rosenthal MA
    J Clin Neurosci; 2012 May; 19(5):633-7. PubMed ID: 22321359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of arterial transit time delays on the differentiation between tumor progression and pseudoprogression in glioblastoma by arterial spin labeling magnetic resonance imaging.
    van Dorth D; Jiang FY; Schmitz-Abecassis B; Croese RJI; Taphoorn MJB; Smits M; Koekkoek JAF; Dirven L; de Bresser J; van Osch MJP
    NMR Biomed; 2024 Sep; 37(9):e5166. PubMed ID: 38654579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advanced Imaging Techniques for Radiotherapy Planning of Gliomas.
    Castellano A; Bailo M; Cicone F; Carideo L; Quartuccio N; Mortini P; Falini A; Cascini GL; Minniti G
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33802292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.